Demographic characteristics of cases and controls included in the InterLymph pooled analysis of family history and risk of NHL
| Demographic characteristics . | Cases, no. (%) . | Controls, no. (%) . |
|---|---|---|
| NHL subtype* | ||
| DLBCL | 3 233 (32) | NA |
| Follicular | 1 979 (19) | NA |
| SLL/CLL | 1 336 (13) | NA |
| SLL† | 416 (4) | NA |
| CLL† | 301 (3) | NA |
| Marginal zone | 380 (4) | NA |
| Mantle-cell | 183 (2) | NA |
| T-cell | 447 (4) | NA |
| Sex | ||
| Men | 5 323 (52) | 6 239 (52) |
| Women | 4 888 (48) | 5 666 (48) |
| Age | ||
| Younger than 20 y | 35 (0.3) | 25 (0.2) |
| 20-29 y | 446 (4) | 640 (5) |
| 30-39 y | 840 (8) | 1 287 (11) |
| 40-49 y | 1 409 (14) | 1 727 (15) |
| 50-59 y | 2 361 (23) | 2 580 (22) |
| 60-69 y | 3 096 (30) | 3 288 (28) |
| 70-79 y | 1 793 (18) | 2 012 (17) |
| 80 y or older | 139 (1) | 156 (1) |
| Race | ||
| White | 9 527 (93) | 11 112 (93) |
| Black | 220 (2) | 330 (3) |
| Other | 464 (5) | 463 (4) |
| Education‡ | ||
| Fewer than 12 y | 3 417 (33) | 3 617 (30) |
| 12-15 y | 4 413 (43) | 5 037 (42) |
| More than 16 y | 2 240 (22) | 3 029 (25) |
| Any first-degree relative with cancer | ||
| None | 9 077 (89) | 10 981 (92) |
| NHL, HL, LK, or MM§ | 648 (6) | 500 (4) |
| NHL/NOS | 201 (2) | 140 (1) |
| Hodgkin lymphoma | 73 (1) | 55 (0.5) |
| Leukemia | 352 (3) | 278 (2) |
| Multiple myeloma | 42 (0.4) | 38 (0.3) |
| Demographic characteristics . | Cases, no. (%) . | Controls, no. (%) . |
|---|---|---|
| NHL subtype* | ||
| DLBCL | 3 233 (32) | NA |
| Follicular | 1 979 (19) | NA |
| SLL/CLL | 1 336 (13) | NA |
| SLL† | 416 (4) | NA |
| CLL† | 301 (3) | NA |
| Marginal zone | 380 (4) | NA |
| Mantle-cell | 183 (2) | NA |
| T-cell | 447 (4) | NA |
| Sex | ||
| Men | 5 323 (52) | 6 239 (52) |
| Women | 4 888 (48) | 5 666 (48) |
| Age | ||
| Younger than 20 y | 35 (0.3) | 25 (0.2) |
| 20-29 y | 446 (4) | 640 (5) |
| 30-39 y | 840 (8) | 1 287 (11) |
| 40-49 y | 1 409 (14) | 1 727 (15) |
| 50-59 y | 2 361 (23) | 2 580 (22) |
| 60-69 y | 3 096 (30) | 3 288 (28) |
| 70-79 y | 1 793 (18) | 2 012 (17) |
| 80 y or older | 139 (1) | 156 (1) |
| Race | ||
| White | 9 527 (93) | 11 112 (93) |
| Black | 220 (2) | 330 (3) |
| Other | 464 (5) | 463 (4) |
| Education‡ | ||
| Fewer than 12 y | 3 417 (33) | 3 617 (30) |
| 12-15 y | 4 413 (43) | 5 037 (42) |
| More than 16 y | 2 240 (22) | 3 029 (25) |
| Any first-degree relative with cancer | ||
| None | 9 077 (89) | 10 981 (92) |
| NHL, HL, LK, or MM§ | 648 (6) | 500 (4) |
| NHL/NOS | 201 (2) | 140 (1) |
| Hodgkin lymphoma | 73 (1) | 55 (0.5) |
| Leukemia | 352 (3) | 278 (2) |
| Multiple myeloma | 42 (0.4) | 38 (0.3) |
For cases, n = 10 211; for controls, n = 11 905. Numbers of cases and controls may not add to total due to missing data; HIV-infected individuals excluded from analysis.
SLL indicates small lymphocytic lymphoma; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; LK, leukemia; MM, multiple myeloma; and NA, not applicable.
USC study enrolled high- and intermediate-grade NHL.
SLL and CLL delineated in Italy, NCI-SEER, UCSF, Nebraska, Mayo Clinic, and Canada.
For UK study, socioeconomic status denoted by Townsend score.
The combined total of individual hematopoietic malignancies is greater than the reported total due to individuals who report a family history of more than one hematopoietic malignancy.